In the closing of the recent trading day, Gilead Sciences (GILD) stood at $87.23, denoting a -1.05% change from the preceding trading day.

A 33-year-old man presented to our dermatology clinic with a 1-month history of two painless ulcers on his right arm and ...

The Center, Native Son, and Gilead present Black, Queer, & Here, a 2024 election forum on key issues facing the Black LGBTQ+ ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains, highlighting the urgent ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...